QURE Quote, Financials, Valuation and Earnings

Merus NV has a net margin of -1940.45% compared to uniQure NV's net margin of -848.67%. uniQure NV's return on equity of -154.29% beat Merus NV's return on equity of -47.97%.

uniQure NV has a consensus price target of $30.72, signalling upside risk potential of 73.29%. On the other hand Merus NV has an analysts' consensus of $86.07 which suggests that it could grow by 99.7%. Given that Merus NV has higher upside potential than uniQure NV, analysts believe Merus NV is more attractive than uniQure NV.

uniQure NV has a beta of 0.895, which suggesting that the stock is 10.539% less volatile than S&P 500. In comparison Merus NV has a beta of 1.071, suggesting its more volatile than the S&P 500 by 7.125%.

uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.

uniQure NV quarterly revenues are $2.3M, which are smaller than Merus NV quarterly revenues of $11.8M. uniQure NV's net income of -$44.4M is higher than Merus NV's net income of -$99.9M. Notably, uniQure NV's price-to-earnings ratio is -- while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 30.01x versus 73.77x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.

Pharming Group has a net margin of -1940.45% compared to uniQure NV's net margin of -1.38%. uniQure NV's return on equity of -154.29% beat Pharming Group's return on equity of -8.24%.

uniQure NV has a consensus price target of $30.72, signalling upside risk potential of 73.29%. On the other hand Pharming Group has an analysts' consensus of -- which suggests that it could grow by 154.72%. Given that Pharming Group has higher upside potential than uniQure NV, analysts believe Pharming Group is more attractive than uniQure NV.

uniQure NV has a beta of 0.895, which suggesting that the stock is 10.539% less volatile than S&P 500. In comparison Pharming Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. Pharming Group pays out -- of its earnings as a dividend.

uniQure NV quarterly revenues are $2.3M, which are smaller than Pharming Group quarterly revenues of $74.8M. uniQure NV's net income of -$44.4M is lower than Pharming Group's net income of -$1M. Notably, uniQure NV's price-to-earnings ratio is -- while Pharming Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 30.01x versus 2.75x for Pharming Group. Usually stocks with elevated PS ratios are considered overvalued.

Pharvaris NV has a net margin of -1940.45% compared to uniQure NV's net margin of --. uniQure NV's return on equity of -154.29% beat Pharvaris NV's return on equity of --.

uniQure NV has a consensus price target of $30.72, signalling upside risk potential of 73.29%. On the other hand Pharvaris NV has an analysts' consensus of -- which suggests that it could grow by 77.3%. Given that Pharvaris NV has higher upside potential than uniQure NV, analysts believe Pharvaris NV is more attractive than uniQure NV.

uniQure NV has a beta of 0.895, which suggesting that the stock is 10.539% less volatile than S&P 500. In comparison Pharvaris NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharvaris NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. Pharvaris NV pays out -- of its earnings as a dividend.

uniQure NV quarterly revenues are $2.3M, which are larger than Pharvaris NV quarterly revenues of --. uniQure NV's net income of -$44.4M is higher than Pharvaris NV's net income of -$45.9M. Notably, uniQure NV's price-to-earnings ratio is -- while Pharvaris NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 30.01x versus -- for Pharvaris NV. Usually stocks with elevated PS ratios are considered overvalued.

ProQR Therapeutics NV has a net margin of -1940.45% compared to uniQure NV's net margin of -210.98%. uniQure NV's return on equity of -154.29% beat ProQR Therapeutics NV's return on equity of -66.59%.

uniQure NV has a consensus price target of $30.72, signalling upside risk potential of 73.29%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $4.10 which suggests that it could grow by 198.51%. Given that ProQR Therapeutics NV has higher upside potential than uniQure NV, analysts believe ProQR Therapeutics NV is more attractive than uniQure NV.

uniQure NV has a beta of 0.895, which suggesting that the stock is 10.539% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.240, suggesting its less volatile than the S&P 500 by 75.965%.

uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.

uniQure NV quarterly revenues are $2.3M, which are smaller than ProQR Therapeutics NV quarterly revenues of $4.2M. uniQure NV's net income of -$44.4M is lower than ProQR Therapeutics NV's net income of -$8.9M. Notably, uniQure NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 30.01x versus 11.27x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.